|
1
|
Macario AJ and Conway de Macario E: Sick
chaperones, cellular stress, and disease. N Engl J Med.
353:1489–1501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Powers MV and Workman P: Inhibitors of the
heat shock response: Biology and pharmacology. FEBS Lett.
581:3758–3769. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garcia-Carbonero R, Carnero A and Paz-Ares
L: Inhibition of HSP90 molecular chaperones: Moving into the
clinic. Lancet Oncol. 14:e358–e369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Welch WJ: The role of heat-shock proteins
as molecular chaperones. Curr Opin Cell Biol. 3:1033–1038. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rowlands MG, Newbatt YM, Prodromou C,
Pearl LH, Workman P and Aherne W: High-throughput screening assay
for inhibitors of heat-shock protein 90 ATPase activity. Anal
Biochem. 327:176–183. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cragg GM and Newman DJ: Plants as a source
of anti-cancer agents. J Ethnopharmacol. 100:72–79. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Whitesell L, Mimnaugh EG, De Costa B,
Myers CE and Neckers LM: Inhibition of heat shock protein
HSP90-pp60v-src heteroprotein complex formation by benzoquinone
ansamycins: Essential role for stress proteins in oncogenic
transformation. Proc Natl Acad Sci USA. 91:8324–8328. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sauville E: Heat shock protein-90 directed
therapeutics and target validation. Cancer Drugs Design and
Discovery. Elsevier; Amsterdam, Netherlands: pp. 336–350. 2008,
View Article : Google Scholar
|
|
9
|
Sharma SV, Agatsuma T and Nakano H:
Targeting of the protein chaperone, HSP90, by the transformation
suppressing agent, radicicol. Oncogene. 16:2639–2645. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lia Y, Zhanga D, Xu J, Shia J, Jiang L,
Yaoa N and Ye W: Discovery and development of natural heat shock
protein 90 inhibitors in cancer treatment. Acta Pharm Sin B.
2:238–245. 2012. View Article : Google Scholar
|
|
11
|
Brough PA, Aherne W, Barril X, Borgognoni
J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG,
Drysdale MJ, et al: 4,5-diarylisoxazole Hsp90 chaperone inhibitors:
Potential therapeutic agents for the treatment of cancer. J Med
Chem. 51:196–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baruchello R, Simoni D, Grisolia G,
Barbato G, Marchetti P, Rondanin R, Mangiola S, Giannini G,
Brunetti T, Alloatti D, et al: Novel 3,4-isoxazolediamides as
potent inhibitors of chaperone heat shock protein 90. J Med Chem.
54:8592–8604. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baruchello R, Simoni D, Marchetti P,
Rondanin R, Mangiola S, Costantini C, Meli M, Giannini G, Vesci L,
Carollo V, et al: 4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as
a new class of cytotoxic Hsp90 inhibitors. Eur J Med Chem.
76:53–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Biamonte MA, Van de Water R, Arndt JW,
Scannevin RH, Perret D and Lee WC: Heat shock protein 90:
Inhibitors in clinical trials. J Med Chem. 53:3–17. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taldone T, Sun W and Chiosis G: Discovery
and development of heat shock protein 90 inhibitors. Bioorg Med
Chem. 17:2225–2235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khan MT, Lampronti I, Martello D, Bianchi
N, Jabbar S, Choudhuri MS, Datta BK and Gambari R: Identification
of pyrogallol as an antiproliferative compound present in extracts
from the medicinal plant Emblica officinalis: Effects on in
vitro cell growth of human tumor cell lines. Int J Oncol.
21:187–192. 2002.PubMed/NCBI
|
|
17
|
Bianchi N, Ongaro F, Chiarabelli C,
Gualandi L, Mischiati C, Bergamini P and Gambari R: Induction of
erythroid differentiation of human K562 cells by cisplatin analogs.
Biochem Pharmacol. 60:31–40. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brognara E, Fabbri E, Bazzoli E, Montagner
G, Ghimenton C, Eccher A, Cantù C, Manicardi A, Bianchi N, Finotti
A, et al: Uptake by human glioma cell lines and biological effects
of a peptide-nucleic acids targeting miR-221. J Neurooncol.
118:19–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lozzio CB and Lozzio BB: Human chronic
myelogenous leukemia cell-line with positive Philadelphia
chromosome. Blood. 45:321–334. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lampronti I, Khan MTH, Borgatti M, Bianchi
N and Gambari R: Inhibitory Effects of Bangladeshi Medicinal Plant
Extracts on Interactions between Transcription Factors and Target
DNA Sequences. Evid Based Complement Alternat Med. 5:303–312. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brognara E, Fabbri E, Montagner G,
Gasparello J, Manicardi A, Corradini R, Bianchi N, Finotti A,
Breveglieri G, Borgatti M, et al: High levels of apoptosis are
induced in human glioma cell lines by co-administration of peptide
nucleic acids targeting miR-221 and miR-222. Int J Oncol.
48:1029–1038. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lampronti I, Borgatti M, Vertuani S,
Manfredini S and Gambari R: Modulation of the expression of the
pro-inflammatory IL-8 gene in cystic fibrosiscells by extracts
deriving from olive mill waste water. Evid Based Complement
Alternat Med. 2013:9606032013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Finotti A, Bianchi N, Fabbri E, Borgatti
M, Breveglieri G, Gasparello J and Gambari R: Erythroid induction
of K562 cells treated with mithramycin is associated with
inhibition of raptor gene transcription and mammalian target of
rapamycin complex 1 (mTORC1) functions. Pharmacol Res. 91:57–68.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fibach E, Prus E, Bianchi N, Zuccato C,
Breveglieri G, Salvatori F, Finotti A, Lipucci di Paola M, Brognara
E, Lampronti I, et al: Resveratrol: Antioxidant activity and
induction of fetal hemoglobin in erythroid cells from normal donors
and β-thalassemia patients. Int J Mol Med. 29:974–982.
2012.PubMed/NCBI
|
|
25
|
Scabini M, Stellari F, Cappella P,
Rizzitano S, Texido G and Pesenti E: In vivo imaging of early stage
apoptosis by measuring real-time caspase-3/7 activation. Apoptosis.
16:198–207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bianchi N, Chiarabelli C, Borgatti M,
Mischiati C, Fibach E and Gambari R: Accumulation of gamma-globin
mRNA and induction of erythroid differentiation after treatment of
human leukaemic K562 cells with tallimustine. Br J Haematol.
113:951–961. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mischiati C, Sereni A, Lampronti I,
Bianchi N, Borgatti M, Prus E, Fibach E and Gambari R:
Rapamycin-mediated induction of gamma-globin mRNA accumulation in
human erythroid cells. Br J Haematol. 126:612–621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Workman P: Pharmacogenomics in cancer drug
discovery and development: Inhibitors of the Hsp90 molecular
chaperone. Cancer Detect Prev. 26:405–410. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schopf FH, Biebl MM and Buchner J: The
HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 18:345–360. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McDonald E, Workman P and Jones K:
Inhibitors of the HSP90 molecular chaperone: Attacking the master
regulator in cancer. Curr Top Med Chem. 6:1091–1107. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gorska M, Popowska U, Sielicka-Dudzin A,
Kuban-Jankowska A, Sawczuk W, Knap N, Cicero G and Wozniak F:
Geldanamycin and its derivatives as Hsp90 inhibitors. Front Biosci.
17:2269–2277. 2012. View
Article : Google Scholar
|
|
32
|
Ward TH, Cummings J, Dean E, Greystoke A,
Hou JM, Backen A, Ranson M and Dive C: Biomarkers of apoptosis. Br
J Cancer. 99:841–846. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gerl R and Vaux DL: Apoptosis in the
development and treatment of cancer. Carcinogenesis. 26:263–270.
2005. View Article : Google Scholar : PubMed/NCBI
|
